1-4 of 4
Jon Travers, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase I/II Study of AZD2811 Nanoparticles (NP) As Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory AML/MDS Patients Not Eligible for Intensive Induction Therapy

William B. Donnellan, MD, Ehab L. Atallah, MD, Adam S. Asch, MD, Manish R. Patel, MD, Jay Yang, MD, Alireza Eghtedar, MD, Gautam M. Borthakur, MD, Julie Charlton, PhD, Alexander MacDonald, MSc-PhD, Anna Korzeniowska, MD, Elizabeth Sainsbury, BSc, Donald K. Strickland, MD, Suzanne Jones, PharmD, Philip Overend, MSc, Carrie A. Adelman, PhD, Giulia Fabbri, MD PhD, Jon Travers, PhD, Simon Smith, PhD, J. Elizabeth Pease, PhD, Jan Cosaert, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3919.
https://doi.org/10.1182/blood-2019-130635
Published: 2019
Journal Articles

Targeting Aurora Kinase B with AZD2811 Enhances Venetoclax Activity in TP53-Mutant AML

Fiona C Brown, Jelena Urosevic, Urszula Polanska, Jan Cosaert, MD PhD, J. Elizabeth Pease, PhD, Giovanna Pomilio, Veronique Litalien, Jon Travers, PhD, Andrew H. Wei
Journal: Blood
Blood (2019) 134 (Supplement_1): 3930.
https://doi.org/10.1182/blood-2019-129564
Published: 2019
Journal Articles

Identification of Novel Combination Therapies Active in BCL2 Inhibitor-Resistant Patient-Derived AML Models

Courtney L Andersen, PhD, Amanda L Christie, MS, Alan Rosen, MS, Kim Maratea, DVM, PhD, Maureen Hattersley, Jon Travers, PhD, Justin Cidado, PhD, Sai Pulukuri, PhD, Jamal Saeh, PhD, Edwin Clark, PhD, Corinne Reimer, PhD, Jerome Mettetal, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1273.
https://doi.org/10.1182/blood-2019-129475
Published: 2019
Journal Articles

A Phase I/II, Open-Label, Multicentre 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticle As Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory Acute Myeloid Leukaemia/Myelodysplastic Syndrome Patients Not Eligible for Intensive Induction Therapy

William B. Donnellan, MD, Ehab L. Atallah, MD, Adam S. Asch, MD, Manish R Patel, MD, Julie Charlton, Alexander MacDonald, Elena Young, Elizabeth Sainsbury, Donald Strickland, MD, Suzanne Jones, PharmD, Philip Overend, Carrie A. Adelman, Jon Travers, PhD, Simon Smith, PhD, J. Elizabeth Pease, PhD, Wolfram Brugger, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4064.
https://doi.org/10.1182/blood-2018-99-118465
Published: 2018